Pacer Advisors Inc. Sells 30,598 Shares of ADMA Biologics Inc (NASDAQ:ADMA)

Key Points

• Pacer Advisors Inc. significantly reduced its stake in ADMA Biologics by selling 30,598 shares, resulting in an 80% decrease in ownership to just 7,632 shares.
• Several other institutional investors also adjusted their positions in ADMA, with notable increases from Farther Finance Advisors LLC and CIBC Private Wealth Group LLC.
• Insider transactions revealed that Directors Jerrold B. Grossman and Lawrence P. Guiheen sold substantial shares, indicating a 2.05% and 17.42% decrease in their respective holdings.

Pacer Advisors Inc. lessened its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 80.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,632 shares of the biotechnology company's stock after selling 30,598 shares during the quarter. Pacer Advisors Inc.'s holdings in ADMA Biologics were worth $151,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ADMA. Tsfg LLC purchased a new stake in ADMA Biologics in the 1st quarter valued at $51,000. Farther Finance Advisors LLC increased its position in shares of ADMA Biologics by 1,149.1% during the 1st quarter. Farther Finance Advisors LLC now owns 2,723 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 2,505 shares during the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of ADMA Biologics during the 4th quarter valued at $85,000. CIBC Private Wealth Group LLC increased its position in shares of ADMA Biologics by 137.1% during the 4th quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock valued at $95,000 after purchasing an additional 2,954 shares during the last quarter. Finally, Covestor Ltd increased its position in shares of ADMA Biologics by 7,038.1% during the 4th quarter. Covestor Ltd now owns 5,996 shares of the biotechnology company's stock valued at $103,000 after purchasing an additional 5,912 shares during the last quarter. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Price Performance

NASDAQ ADMA traded down $0.26 during trading hours on Wednesday, hitting $18.70. The company had a trading volume of 1,261,209 shares, compared to its average volume of 3,055,910. ADMA Biologics Inc has a 52 week low of $11.42 and a 52 week high of $25.67. The firm has a 50 day simple moving average of $18.78 and a 200 day simple moving average of $18.81. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.36 and a current ratio of 6.58. The firm has a market capitalization of $4.47 billion, a price-to-earnings ratio of 22.04 and a beta of 0.38.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.02). The business had revenue of $114.80 million for the quarter, compared to analysts' expectations of $116.40 million. ADMA Biologics had a return on equity of 47.16% and a net margin of 45.01%. The firm's revenue for the quarter was up 40.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.08 EPS. Equities research analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Steve Elms sold 194,749 shares of the business's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the sale, the director owned 87,330 shares in the company, valued at $1,767,559.20. The trade was a 69.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Lawrence P. Guiheen sold 20,000 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $20.96, for a total value of $419,200.00. Following the completion of the sale, the director owned 94,830 shares of the company's stock, valued at $1,987,636.80. The trade was a 17.42% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 464,621 shares of company stock valued at $9,644,269 in the last quarter. Corporate insiders own 3.50% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ADMA. Raymond James Financial raised their target price on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th. Wall Street Zen lowered ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.